- Details
- Zach Klaassen and Geoffrey Johnson discuss the SECuRE trial, a phase 1-2 dose escalation expansion study of a PSMA-targeted radiopharmaceutical for prostate cancer using copper 67. This innovative therapy boasts a unique chelator, enhancing drug delivery and reducing systemic leakage. Early results demonstrate promising efficacy and safety, with notable responses observed in patients, including co...
|
- Details
- Alexandra Sokolova discusses her team's study on genomic alterations influencing the response to lutetium-177 PSMA in metastatic castration-resistant prostate cancer. Their research highlights the need for better biomarkers to predict patient outcomes with lutetium-177 PSMA, as not all patients respond to this treatment. Utilizing data from a collaborative database of over 2000 patients, Dr. Sokol...
|
- Details
- Matthew Smith presents the primary analysis of the CYCLONE 2 trial. This global randomized controlled trial investigated the combination of abemaciclib, a CDK4/6 inhibitor, with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the promising biological rationale and preclinical evidence suggesting potential benefits, the trial did...
|
- Details
- Tanya Dorff discusses her team's Phase 1 trial on PSCA CAR T cell therapy for metastatic castration-resistant prostate cancer, published in Nature Medicine. Dr. Dorff highlights that prostate cancer's immunosuppressive environment poses significant challenges, making the development of potent therapies like CAR T cells crucial. The trial involved administering CAR T cells, initially without and th...
|
- Details
- Michael Schweizer discusses findings on Mevrometostat, an EZH2 inhibitor, combined with enzalutamide in treating metastatic castration-resistant prostate cancer (mCRPC). Dr. Schweizer highlights that EZH2 is a significant driver in neuroendocrine prostate cancer (NEPC) development, making it a crucial target for treatment. The Phase I/II trial shows that Mevrometostat combined with enzalutamide yi...
|
- Details
- Ali Sabbagh presents a novel study on using machine learning to predict overall survival in clinical trials for metastatic prostate cancer. Dr. Sabbagh explains that traditional endpoints like overall survival often require long follow-ups, delaying access to potentially life-saving treatments. His research leverages baseline clinical characteristics and PSA changes over four months to accelerate...
|
- Details
- Edmond Kwan discusses his latest research on circulating tumor DNA (ctDNA) as a predictive marker for response to Lutetium PSMA-617 versus cabazitaxel. The Phase II TheraP trial compared these treatments in patients with advanced metastatic castration-resistant prostate cancer, utilizing dual imaging selection. Dr. Kwan highlights that ctDNA fraction, the proportion of tumor-derived DNA in circula...
|
- Details
- Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...
|
- Details
- Zach Klaassen speaks with Mark Markowski about the advancements in AI, particularly the ArteraAI Prostate Test, and its implications for prostate cancer treatment. Dr. Markowski explains how ArteraAI has evolved from predicting treatment responses in localized prostate cancer to potentially guiding treatment decisions in metastatic hormone-sensitive prostate cancer. The CHAARTED study, a pivotal t...
|
- Details
- Zach Klaassen and Benjamin Maughan discuss new insights into the real-world application of apalutamide in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Maughan highlights the significance of achieving deep PSA responses as a key prognostic marker for patient outcomes. The OASIS project, utilizing data from diverse medical settings across the U.S., demonstrates that patients wh...
|
